Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.

@article{Dogn2005ThromboxanePA,
  title={Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.},
  author={J M Dogn{\'e} and Julien Hanson and Domenico Pratic{\`o}},
  journal={Trends in pharmacological sciences},
  year={2005},
  volume={26 12},
  pages={639-44}
}
Atherosclerosis is a chronic disease of the vasculature that is influenced by multiple factors that involve a complex interplay between some components of the blood and the arterial wall. Inflammation and oxidative stress have key roles in atherogenesis. The production of F2-isoprostanes (F2-IPs), thromboxane A2 (TxA2) and prostacyclin (PGI2) increases in atherosclerosis, and recent studies show that pharmacological modulation of their biosynthesis and biological activities are important… CONTINUE READING
42 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Similar Papers

Loading similar papers…